How antidepressants change brain cell signaling connected to BDNF
Antidepressants and Intracellular Signaling Linked to BDNF
Looking at how certain antidepressants trigger BDNF-related brain signals to produce rapid relief for people with depression.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11319026 on NIH RePORTER |
What this research studies
From my perspective as a patient, researchers are studying how drugs like ketamine act in the brain to produce fast antidepressant effects by increasing BDNF protein in the hippocampus. They use mice with specific genes turned off (BDNF or its receptor TrkB) and laboratory measures of synaptic signaling to trace the steps from NMDA receptor blockade to increased protein translation. The team examines how blocking NMDA receptors affects eEF2 kinase and eEF2 to boost production of BDNF and how BDNF leads to insertion of AMPA receptors at synapses. Although most work is in animals and tissue, the goal is to map molecular steps that could guide faster-acting treatments for people.
Who could benefit from this research
Good fit: Adults with major depressive disorder, particularly those with treatment-resistant depression or who need rapid symptom relief, are the most relevant group for future clinical applications.
Not a fit: People with non-depressive conditions, mild situational sadness, or forms of depression not driven by glutamatergic/BDNF mechanisms may not see direct benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could reveal targets for faster-acting antidepressant treatments that help people feel better sooner.
How similar studies have performed: Ketamine already produces rapid antidepressant effects in humans and animals and prior animal work implicates BDNF, but detailed intracellular signaling steps remain partly novel and under active study.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Monteggia, Lisa M — Vanderbilt University
- Study coordinator: Monteggia, Lisa M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.